Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Eur Addict Res. 2017;23(4):211-218. doi: 10.1159/000480380. Epub 2017 Sep 13.
The objective of this retrospective study was to compare the effectivity and tolerability of diazepam and clomethiazole in the treatment of alcohol withdrawal syndrome (AWS) in a large clinical sample.
The data of 566 patients admitted to an intensive care psychiatric unit in Germany (2010-2014) were evaluated. The course of withdrawal was analyzed on a matched sample (n = 152) consisting of a diazepam group (n = 76) and a clomethiazole group (n = 76). Medical assessment was based on a standardized point-based symptom rating scale called AESB (Alkoholentzugssymptom-Bogen), a German modified version of the Revised Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar).
Although the mean daily symptom reduction did not differ significantly, patients treated with clomethiazole were treated significantly shorter and needed less concomitant antipsychotic medication. Numbers of complications and adverse events did not show significant differences.
Both clomethiazole and diazepam were effective and equally safe in the treatment of AWS. Clomethiazole provided a faster withdrawal and required less concomitant antipsychotic medication and therefore might be the more favorable option for patients and physicians. Taken into account the methodological limitations of the study (retrospective design, secondary matching, missing randomization, use of clomethiazole as drug of first choice), further studies are needed to confirm this result.
本回顾性研究的目的是在一个大的临床样本中比较地西泮和氯美噻唑治疗酒精戒断综合征(AWS)的疗效和耐受性。
评估了 2010 年至 2014 年间在德国一家重症精神科病房住院的 566 名患者的数据。在一个匹配样本(n = 152)中分析了戒断过程,该样本包括地西泮组(n = 76)和氯美噻唑组(n = 76)。医疗评估基于一种名为 AESB(Alkoholentzugssymptom-Bogen)的标准化基于点的症状评分量表,这是修订后的临床酒精戒断评估量表(CIWA-Ar)的德国改良版。
尽管平均每日症状缓解差异无统计学意义,但接受氯美噻唑治疗的患者治疗时间明显缩短,需要的抗精神病药物也较少。并发症和不良事件的数量没有显示出显著差异。
氯美噻唑和地西泮在治疗 AWS 方面均有效且同样安全。氯美噻唑提供了更快的戒断速度,需要较少的抗精神病药物辅助治疗,因此可能是患者和医生更倾向的选择。考虑到研究的方法学限制(回顾性设计、二次匹配、随机缺失、氯美噻唑作为首选药物的使用),需要进一步的研究来证实这一结果。